SCHEMBL15052061

SCHEMBL15052061

CC1(C)C=Cc2cc(CN(C3CCC3)S(=O)(=O)c3ccccn3)ccc2O1

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ EP300 Q09472 4/20 0.68
▸ HIF1A Q16665 16/20 0.63
▸ EPAS1 Q99814 16/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051844 0.99 EP300 (0.67) EP300HIF1AEPAS1
SCHEMBL15052432 0.97 EP300 (0.69) EP300HIF1AEPAS1
SCHEMBL15052240 0.85 EP300 (0.74) EP300HIF1AEPAS1
SCHEMBL15052348 0.83 EP300 (0.78) EP300HIF1AEPAS1
SCHEMBL15051967 0.81 EP300 (1.00) EP300HIF1AEPAS1
SCHEMBL2563997 0.77 HIF1A (1.00) EP300HIF1AEPAS1
SCHEMBL14916511 0.76 HIF1A (1.00) EP300HIF1AEPAS1
SCHEMBL16496888 0.75 HIF1A (1.00) EP300HIF1AEPAS1
SCHEMBL14916669 0.75 HIF1A (1.00) EP300HIF1AEPAS1
SCHEMBL2564310 0.73 HIF1A (1.00) EP300HIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130164218-A1 HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS EMORY UNIVERSITY (US) 2013-06-27 — — US claimed
US-9381260-B2 Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents EMORY UNIVERSITY (US) 2016-07-05 — — US disclosed
US-9381260-B2 Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents EMORY UNIVERSITY (US) 2016-07-05 — — US disclosed
US-9381260-B2 Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents EMORY UNIVERSITY (US) 2016-07-05 — — US disclosed
US-20130164218-A1 HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS EMORY UNIVERSITY (US) 2013-06-27 — — US disclosed
US-20130164218-A1 HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS EMORY UNIVERSITY (US) 2013-06-27 — — US disclosed
US-20130164218-A1 HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS EMORY UNIVERSITY (US) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130164218-A1 HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES AS ANTICANCER AND IMAGING AGENTS HIF1A, HIF1AN, HYOU1 EP300 505/4885HIF1A 1/4885EPAS1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback